SCHEMBL4842364

SCHEMBL4842364

COc1ccc2c(COc3ccccc3)nnc(Cl)c2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.49
PDE4B Q07343 7/20 0.49
PDE4C Q08493 7/20 0.49
PDE4D Q08499 7/20 0.49
MAOB P27338 3/20 0.43
MAPT P10636 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP19A1 P11511 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
KDR P35968 1/20 0.39
ALDH1A1 P00352 2/20 0.39
BCHE P06276 1/20 0.38
VCP P55072 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125179 0.84 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4841956 0.84 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DMAOB
SCHEMBL4838839 0.82 ALDH1A1 (0.54) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4843440 0.81 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4124808 0.80 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL26690613 0.77 KDM4E (0.45) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4843309 0.75 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4845442 0.74 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4838830 0.74 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DCYP19A1
SCHEMBL6585470 0.74 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 PDE4A 1615/4885PDE4B 1845/4885PDE4C 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.